Everything below concerns Water activity. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-06-17. Numbers and descriptions here follow the published literature rather than marketing material.
Analytical testing for whey protein hydrolysate focuses on peptide size distribution, degree of hydrolysis, protein content, moisture, ash, and microbiological quality. Size-exclusion chromatography and mass spectrometry can characterize peptide profiles, while Kjeldahl or combustion methods estimate total nitrogen and protein. Amino acid analysis quantifies free and total amino acids. Because peptide mixtures are complex, no single method captures every property, and results can vary between laboratories. Standardized methods and reference materials help improve comparability, but full sequence-level characterization remains uncommon in routine quality control.
Regulatory treatment of whey protein hydrolysate depends on the country and intended use. In many jurisdictions it is regulated as a food ingredient or food for special dietary use, not as a drug. Labeling rules govern allergen statements, protein content claims, and ingredient names. Some markets have specific rules for infant formula ingredients, where hydrolysates may be used for particular dietary purposes. Regulations generally focus on safety, truthful labeling, and manufacturing standards rather than on therapeutic effects. Scientific questions about specific peptide activities remain an active area of research rather than a settled regulatory category.
Physical properties such as particle size, bulk density, and reconstitution behavior affect handling and finished product quality. Water activity and moisture content influence shelf life; high moisture can promote caking, browning, and microbial growth. Color is monitored because Maillard reactions between peptides and reducing sugars can darken the powder during storage. Taste panels and instrumental methods may assess bitterness, which is a common challenge for hydrolysates. Specifications often include limits for heavy metals, microbiological counts, and residual fat, depending on the intended market.
Quality control for hydrolyzed whey protein focuses on composition, peptide size, and batch consistency. Protein content is commonly measured by Kjeldahl or combustion analysis, while moisture and ash are determined by gravimetric methods. Peptide molecular weight distribution is often assessed by size exclusion chromatography or mass spectrometry. The extent of hydrolysis can be estimated by titration, trinitrobenzenesulfonic acid assays, or formol titration. Because hydrolysis produces a complex mixture, no single test captures every relevant property, and laboratories often combine several methods.
| Property | Value | Notes |
|---|---|---|
| Moisture content | Typically below 6% for dry powders | Higher moisture can promote caking and degradation. |
| Water activity | Often below 0.6 | Low water activity limits microbial growth. |
| Typical storage temperature | 15–25 °C (cool, dry) | Avoid heat and humidity; follow label specifications. |
| Common analytical method | Size-exclusion chromatography | Used to estimate peptide molecular weight distribution. |
| Common synonym | Hydrolyzed whey protein | Not identical to whey protein isolate or concentrate. |
The parent whey proteins include beta-lactoglobulin, alpha-lactalbumin, serum albumin, immunoglobulins, and glycomacropeptide, depending on the whey source. Hydrolysis does not remove these sequences; it fragments them into peptides of varying length. The peptide distribution depends on the enzyme specificity, reaction time, temperature, pH, and enzyme-to-substrate ratio. Because the mixture is heterogeneous, a single molecular weight cannot describe the product. Instead, laboratories report a distribution, often spanning from a few hundred to several thousand daltons.
Whey protein hydrolysate appears in foods and supplements where rapid digestion, low viscosity, or reduced intact-protein content is desired. It is distinct from whey protein isolate and concentrate, which contain largely intact proteins, though hydrolysates can be made from either. In infant formula, extensively hydrolyzed whey is used in some specialty products, while partially hydrolyzed forms appear in other formulations. Human health effects depend on the specific peptide mixture and are not uniform across all hydrolysates.
Quality control for whey protein hydrolysate begins with specification of protein, moisture, ash, fat, lactose, and degree of hydrolysis, while molecular weight distribution is measured by size-exclusion chromatography or electrophoresis. Free amino acid content can be quantified by amino acid analysis. Microbial limits, heavy metals, and residual enzyme activity are also monitored. Because hydrolysis conditions influence batch consistency, manufacturers validate processes and test each lot against release criteria. Sampling plans and reference standards help compare results across laboratories.
Storage stability depends on moisture, temperature, oxygen, and packaging, and hydrolysates are hygroscopic and can cake when exposed to humid air. Maillard reactions between peptides and residual lactose can cause browning and flavor changes during warm storage, while lipid oxidation may develop if residual fat is present. Cool, dry conditions and sealed containers slow these reactions. Shelf-life studies typically monitor moisture, color, solubility, molecular weight profile, and microbial counts over time. Accelerated tests estimate stability, but real-time data remain the reference for shelf-life assignment.
Whey protein hydrolysate is a dairy-derived ingredient made by treating whey protein with enzymes or acid to break peptide bonds. The starting material is typically sweet whey or acid whey from cheese manufacture, which contains beta-lactoglobulin, alpha-lactalbumin, bovine serum albumin, and immunoglobulins. Hydrolysis shortens protein chains into peptides and free amino acids, changing solubility, viscosity, and taste. The extent of breakdown is described by degree of hydrolysis, a percentage of cleaved peptide bonds. This value influences functional and sensory properties but does not by itself define a specific molecular profile.
Commercial production usually begins with whey protein concentrate or isolate, not raw whey, to reduce fat and lactose. Food-grade proteases from bacterial or plant sources are added under controlled temperature and pH, then inactivated by heat or pH adjustment. The resulting liquid may be clarified, filtered, concentrated, and spray-dried into powder. Enzyme choice, reaction time, and pretreatment conditions create products with different peptide size distributions. Because these variables are proprietary and not standardized, two hydrolysates with the same degree of hydrolysis can differ in peptide sequences and mineral content.
Composition reflects both the original whey and the hydrolysis process. Products contain protein-derived peptides, variable ash, moisture, and residual lactose or fat depending on filtration. Some free amino acids increase during hydrolysis, and bitterness often rises with higher degrees of hydrolysis due to exposed hydrophobic residues. Mineral profiles vary with the whey source and any neutralization step. Allergenicity may be reduced in extensively hydrolyzed products, but the extent depends on residual intact protein and peptide size, and this remains a subject of ongoing study.
state of Oklahoma to settle allegations that it had been overprescribing opioids, marketing them as safe, and downplaying their addictive qualities. In July 2019, Teva paid $69 million to settle pay-for-delay claims. In January 2020, Teva Pharmaceuticals agreed to pay $54 million to settle allegations under the False Claims Act that it violated the Anti-Kickback Statute by funding improper speaking programs to boost prescriptions. In 2021, New York Attorney General Letitia James filed a lawsuit against Teva and several other opioid manufacturers for their alleged contribution to the opioid epidemic in New York. In February 2022, Teva agreed to a $225 million settlement with the state of Texas to end claims that it fueled an opioid epidemic in the state by improperly marketing pain medicine. In August 2023, Teva admitted to price-fixing charges related to the generic cholesterol drug Pravastatin, and agreed to pay a $225 million fine, after a criminal investigation by the US Department of Justice. The US Department of Justice stated that the settlement was "the largest to date for a domestic antitrust cartel." Also in August 2023, Teva agreed to a legal settlement with US hospitals over its marketing of opioid products that ultimately raised costs for health providers and contributed to the opioid epidemic in the United States. The lawsuit consisted of roughly 500 hospitals and health providers, resulting in a payment from Teva of $126 million over 18 years.
== Stability == Avobenzone is sensitive to the properties of the solvent, being relatively stable in polar protic solvents and unstable in nonpolar environments. Also, when it is irradiated with UVA light, it generates a triplet excited state in the keto form which can either cause the avobenzone to degrade or it can transfer energy to biological targets and cause deleterious effects. Avobenzone has been shown to degrade significantly in light, resulting in less protection over time. The UV-A light in a day of sunlight in a temperate climate is sufficient to break down most of the compound. Data presented to the Food and Drug Administration by the Cosmetic, Toiletry and Fragrance Association indicates a −36% change in avobenzone's UV absorbance following one hour of exposure to sunlight. For this reason, in sunscreen products, avobenzone is always formulated together with a photostabilizer, such as octocrylene. Other photostabilizers include:
== Initiation == Initiation of translation in bacteria involves the assembly of the components of the translation system, which are: the two ribosomal subunits (50S and 30S subunits); the mature mRNA to be translated; the tRNA charged with N-formylmethionine (the first amino acid in the nascent peptide); guanosine triphosphate (GTP) as a source of energy, and the three bacterial initiation factors IF1, IF2, and IF3, which help the assembly of the initiation complex. Variations in the mechanism can be anticipated. The ribosome has three active sites: the A site, the P site, and the E site. The A site is the point of entry for the aminoacyl tRNA (except for the first aminoacyl tRNA, which enters at the P site). The P site is where the peptidyl tRNA is formed in the ribosome. And the E site which is the exit site of the now uncharged tRNA after it gives its amino acid to the growing peptide chain.
==== Indigenous ==== Black bears feature prominently in the stories of some of North America's indigenous peoples. One tale tells of how the black bear was a creation of the Great Spirit, while the grizzly bear was created by the Evil Spirit. In the mythology of the Haida, Tlingit and Tsimshian people of the northwest coast, mankind first learned to respect bears when a girl married the son of a black bear chieftain. In Kwakwa̱ka̱ʼwakw mythology, black and brown bears became enemies when Grizzly Bear Woman killed Black Bear Woman for being lazy. Black Bear Woman's children, in turn, killed Grizzly Bear Woman's children. The Navajo believed that the Big Black Bear was chief among the bears of the four directions surrounding Sun's house and would pray to it in order to be granted its protection during raids. Sleeping Bear Dunes in Michigan is named after a Native American legend, where a female bear and her two cubs swam across Lake Michigan to escape a fire on the Wisconsin shore. The mother bear reached the shore and waited for her cubs, but they did not make it across. Two islands mark where the cubs drowned, while the dune marks the spot where the mother bear waited.
== History == Protein C's anticoagulant role in the human body was first noted by Seegers et al. in 1960, who gave protein C its original name, autoprothrombin II-a. Protein C was first isolated by Johan Stenflo from bovine plasma in 1976, and Stenflo determined it to be a vitamin K-dependent protein. He named it protein C because it was the third protein ("peak C") that eluted from a DEAE-Sepharose ion-exchange chromotograph. Seegers was, at the time, searching for vitamin K-dependent coagulation factors undetected by clotting assays, which measure global clotting function. Soon after this, Seegers recognised Stenflo's discovery was identical with his own. Activated protein C was discovered later that year, and in 1977 it was first recognised that APC inactivates Factor Va. In 1980, Vehar and Davie discovered that APC also inactivates Factor VIIIa, and soon after, Protein S was recognised as a cofactor by Walker. In 1982, a family study by Griffin et al. first associated protein C deficiency with symptoms of venous thrombosis. Homozygous protein C deficiency and the consequent serious health effects were described in 1984 by several scientists. cDNA cloning of protein C was first performed in 1984 by Beckmann et al. which produced a map of the gene responsible for producing protein C in the liver. In 1987 a seminal experiment was performed (Taylor et al.) whereby it was demonstrated that activated protein C prevented coagulopathy and death in baboons infused with lethal concentrations of E. coli. In 1993, a heritable resistance to APC was detected by Dahlbäck et al.
Sources: en.wikipedia.org
== Examples == If [Ru(NH3)5]3+ is attached to certain histidine residues in a myoglobin protein, myoglobin is no longer a passive oxygen carrier, but gains enzymatic activity of an oxidase. Ascorbic acid is oxidised with molecular oxygen. Cyclodextrins are cap structures with a hydrophilic exterior but a hydrophobic interior. If pyridoxal is anchored in the interior the cyclodextran shows transaminase activity.
=== Growth and expansion === In 1997, Medtronic opened a production site for implantable pacemakers and brain pacemakers in Tolochenaz, Switzerland. One in five pacemakers implanted globally today is made here. The site is also used as a European training centre for doctors. In 1998, Medtronic acquired Physio-Control for $538 million. In 2014, Integra LifeSciences announced it was acquiring instrumentation lines from Medtronic for $60 million. The deal included Medtronic's MicroFrance and Xomed manual ear, nose and throat and laparoscopic surgical instruments, as well as a manufacturing facility in France. In February 2016, the company announced that it would acquire Bellco from private equity firm Charme Capital Partners. In June, the company announced its acquisition of HeartWare International Inc. for $1.1 billion. In December 2017, Medtronic acquired Crospon for €38 million (approximately $45 million). In September 2018, the company acquired Mazor Robotics for $1.64 billion ($58.50 per American Depository Share or $29.25 per ordinary share. In late November, Medtronic acquired Nutrino Health Ltd boosting the company's nutrition-related data services and analytics. In March 2017, Bloomberg's database of U.S. tax inversions listed Medtronic and Wright Medical Group (Medtronic's 2015 inversion to Ireland was over $100 billion, while Wright's 2015 inversion to the Netherlands was $3.3 billion) as the only U.S. tax inversions of a U.S. medical device company in history.
An aortogram involves injection of contrast material while taking X-rays of the aorta. Once commonly used, its use has since been supplanted by less invasive and more sensitive imaging modalities. The American Heart Association does not recommend the use of aortograms as a first line imaging modality in the diagnoses of aortic dissections. They note that aortograms have limited sensitivity and are more invasive than other tests.
Rhabdomyolysis (shortened as rhabdo) is a condition in which damaged skeletal muscle breaks down rapidly. Symptoms may include muscle pains, weakness, vomiting, and confusion. There may be tea-colored urine or an irregular heartbeat. Some of the muscle breakdown products, such as the protein myoglobin, are harmful to the kidneys and can cause acute kidney injury. The muscle damage is usually caused by a crush injury, strenuous exercise, medications, or a substance use disorder. Other causes include infections, seizure, electrical injury, heat stroke, prolonged immobilization, lack of blood flow to a limb, or snake bites as well as intense or prolonged exercise, particularly in hot conditions. Rhabdomyolysis can occur in athletes Statins (a class of prescription drugs to lower cholesterol) are considered a small risk. Some people have inherited muscle conditions that increase the risk of rhabdomyolysis. The diagnosis is supported by a urine test strip which is positive for "blood" but the urine contains no red blood cells when examined with a microscope. Blood tests show a creatine kinase activity greater than 1000 U/L, with severe disease being above 5000–15000 U/L. The mainstay of treatment is large quantities of intravenous fluids. Other treatments may include dialysis or hemofiltration in more severe cases. Once urine output is established, sodium bicarbonate and mannitol are commonly used but they are poorly supported by the evidence. Outcomes are generally good if treated early.
Sources: en.wikipedia.org
Fibroblast stimulation. It is thought that fibroblast stimulation by the thyroid stimulating hormone (TSH) receptor increases the deposition of glycosaminoglycan, which results in an osmotic edema and fluid retention. It is thought that many cells responsible for forming connective tissue react to increases in TSH levels. Lymphocyte stimulation. In Graves' thyroid disease, lymphocytes react against the TSH receptor by inappropriately producing thyroid-stimulating immunoglobulin (IgG; type II hypersensitivity). Lymphocytes react not only against thyroid receptors, but also any tissue with cells expressing the receptor. This can lead to tissue damage and scar tissue formation, explaining the deposition of glycosaminoglycans.
The most basic approach is to manipulate the various equilibrium constants until the desired concentrations are expressed in terms of measured equilibrium constants (equivalent to measuring chemical potentials) and initial conditions. Minimize the Gibbs energy of the system. Satisfy the equation of mass balance. The equations of mass balance are simply statements that demonstrate that the total concentration of each reactant must be constant by the law of conservation of mass.
25 July What would become known as the "Nixon Doctrine" was outlined for the first time in an informal press conference with reporters who had accompanied Nixon to Guam during his Asian tour. In remarks later published, but given at the time "for attribution but not direct quotation", Nixon said, "I believe that the time has come when the United States, in our relations with all of our Asian friends, be quite emphatic on two points: One, that we will keep our treaty commitments... but, two, that as far as the problems of internal security are concerned, as far as the problems of military defense... that the United States is going to encourage and has a right to expect that... the responsibility for it taken by, the Asian nations themselves."
Sources: en.wikipedia.org
It is generally stored in a sealed container in a cool, dry place away from strong odors. Moisture and heat can cause caking, flavor changes, and peptide degradation. Product-specific labels and stability data should guide actual storage conditions.
Common tests measure moisture, water activity, protein content, ash, microbiological safety, and degree of hydrolysis. Peptide size distribution may be checked by chromatography. Not every batch receives full sequence-level analysis because such testing is complex and costly.
Not necessarily, because hydrolysis can reduce the size of some allergenic proteins while residual allergenic sequences may remain depending on the process. Milk is still a major allergen, and labeling rules usually require milk allergen disclosure unless a specific exemption applies. The term hydrolysate alone does not establish hypoallergenicity.
Size exclusion chromatography separates peptides by molecular size in solution, and mass spectrometry can provide more detailed mass information. Results are usually reported as a distribution rather than a single value. Method choice and calibration affect the reported range.